


## Nitroaspirin

Cat. No.:	HY-123823
CAS No.:	175033-36-0
Molecular Formula:	C <sub>16</sub> H <sub>13</sub> NO <sub>7</sub>
Molecular Weight:	331.28
Target:	COX; Apoptosis
Pathway:	Immunology/Inflammation; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

Description	Nitroaspirin (NCX 4016) is a nitric oxide (NO) donor and a nitro-derivative of Aspirin, which combines with Nitroaspirin to inhibit cyclooxygenase. Nitroaspirin (NCX 4016) has antithrombotic and anti-platelet properties and acts as a direct and irreversible inhibitor of COX-1. Nitroaspirin (NCX 4016) causes significant induction of cell cycle arrest and apoptosis in Cisplatin-resistant human ovarian cancer cells via down-regulation of EGFR/PI3K/STAT3 signaling and modulation of Bcl-2 family proteins <sup>[1][2][3][4]</sup> .
IC <sub>50</sub> & Target	COX-1

### REFERENCES

- [1]. Selvendiran K, et al. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. *Cell Cycle*. 2008 Jan 1;7(1):81-8.
- [2]. Bertuglia S, et al. Antioxidant activity of nitro derivative of aspirin against ischemia-reperfusion in hamster cheekpouch microcirculation. *Am J Physiol Gastrointest Liver Physiol*. 2004 Mar;286(3):G437-43.
- [3]. Corazzi T, et al. Direct and irreversible inhibition of cyclooxygenase-1 by nitroaspirin (NCX 4016). *J Pharmacol Exp Ther*. 2005 Dec;315(3):1331-7.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA